The observation that co-treatment with BSO, which depletes glutathione, significantly enhanced RK-33 cytotoxicity suggests a potential therapeutic strategy that exploits oxidative stress to maximize the impact of DDX3X inhibition in B-cell lymphoma. This evidence concerns the gene DDX3X and B-cell non-Hodgkin lymphoma.